Can a Cholesterol Drug Prevent Colon Cancer?

	Tweet

Thomas Jefferson University has started recruiting patients for a new National Cancer Institute (NCI)-sponsored clinical trial to test whether the cholesterol-reducing drug rosuvastatin is effective in the prevention of recurrent colon cancer.

Previous laboratory research and population studies have shown that patients taking Statins, the class of drugs that lowers cholesterol, had fewer colon polyps, which can lead to cancer if left untreated. However, those findings come largely from retrospective, observational studies originally designed to investigate lipid-lowering or cardiovascular endpoints in the short term rather than tumor endpoints.

“The jury is still out, and we need to get definitive answers,” said Bruce Boman, M.D., Ph.D, professor of medical oncology at Thomas Jefferson University and principal investigator for the national clinical trial. “This prospective design comparing a statin against a placebo is what is needed to address the question: Are Statins effective chemoprevention agents or not?”

This five-year, nationwide study will be the first randomized, prospective, placebo-controlled, double-blind study to evaluate the drug’s role in preventing colon cancer and will involve 1,740 patients in total.

Conducted by a network of cancer research professionals from the National Surgical Adjuvant Breast and Bowel Project (NSABP) at 400 medical centers across North America, including Jefferson, the study involves patients who have recently been diagnosed with early stage colon cancer, and who were not already taking Statins for High cholesterol. Those recruited have been surgically treated for stage I and II colon cancers previously.

Patients will be randomly assigned to one of two groups. Each group will take one pill a day for five years. One group will receive rosuvastatin, while the other group will receive a placebo.

The cumulative incidence for developing colorectal adenomas three years after surgery/treatment for early stage colon cancer is 50 percent. Thus, the benefit/risk ratio for chemoprevention intervention is potentially very positive in this high-risk population.

“There will be an estimated 102,900 new cases of colon cancer in the United States this year,” said Norman Wolmark, M.D., NSABP’s chairman. “In fact, colorectal cancer is the third most common cancer found in men and women in this country. We hope this trial will be an important step in reducing these numbers.”

The principal investigator for the trial at Jefferson is Scott Goldstein, M.D, director of the Division of Colon and Rectal Surgery at Thomas Jefferson University.

People recently diagnosed with a Stage I or II colon cancer and interested in the study should contact Vicki Squire of Thomas Jefferson University at or 215-503-5641.

A list of other sites in North America that are participating in the study may be found at http://www.nsabp.pitt.edu/P5_Sites.asp

March 2011 is National Colorectal Cancer Awareness Month

###

Source: Thomas Jefferson University

RELATED STORIES:
Women fare better than men with metastatic colorectal cancer—are hormones helping?   Activation of Biomarker Linked with Improved Survival Among Obese Patients with Colorectal Cancer   Does sex matter in colon cancer screening?   Cocoa could prevent intestinal pathologies such as colon cancer   Consistent exercise associated with lower risk of colon cancer death   Lights, Camera, Colonoscopy: What to Expect When Your Doctor Wants an Inside Look   Use of Chemotherapy After Surgery for Colon Cancer Has Risen   Black Raspberries May Slow Growth of Colon, Other Cancers   Celecoxib May Help Prevent Colorectal Cancer In High Risk Patients   Curry compound may prevent colon cancer   Blood pressure drugs don’t protect against colorectal cancer   Chemical changes may help detect colon cancer early   Statins don’t protect against cancer: study   Can a Mediterranean Diet Help Prevent Colon Cancer?   Provider influence and patient barriers affect use of colorectal cancer screening   Aspirin vs. colon cancer: study weighs benefits   ‘Cross-talk’ Mechanism Contributes to Colorectal Cancer   Most Adults Don’t Realize Activity Lowers Colon Cancer Risk   A gene for metastasis   Stool Testing Novel Technique for Detecting Colon Cancer   B Vitamins in Mother’s Diet Reduce Colorectal Cancer Risk in Offspring   HBV infection decreases risk of liver metastasis in colorectal cancer patients

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]